By Professor Jason Grebely

Conference Abstracts

Kwon AJ; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Estes C; Razavi H; Gray RT, 2017, 'O12 Australia could meet the WHO HCV elimination targets if the current rollout of DAA treatment is continued', in Journal of Virus Eradication, Elsevier BV, Vol. 3, pp. 5 - 5, http://dx.doi.org/10.1016/s2055-6640(20)30895-5

Dore G; Grebely J; Altice F; Litwin AH; Dalgard O; Gane EJ; Shibolet O; Luetkemeyer A; Nahass R; Peng C-Y; Conway B; Iser DM; Huang H-C; Gendrano IN; Kelly MM; Hwang P; Robertson M; Wahl J; Barr E; Platt HL, 2016, 'HCV reinfection and injecting risk behavior following elbasvir/grazoprevir treatment in patients on opioid agonist therapy: Co-STAR Three Year Follow-up Study', in HEPATOLOGY, WILEY, MA, Boston, Vol. 64, pp. 431A - 431A, presented at 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), MA, Boston, 11 November 2016 - 15 November 2016

Larney S; Grebely J; Degenhardt L; Amin J; Law M; Alavi M; Dore GJ; Law M, 2016, 'EXPOSURE TO OPIOID SUBSTITUTION THERAPY FOLLOWING HEPATITIS C NOTIFICATION: IMPLICATIONS FOR PROVISION OF ANTIVIRAL THERAPIES IN DRUG TREATMENT SETTINGS', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 35, pp. 48 - 48

Grebely J; Mauss S; Brown A; Bronowicki J-P; Puoti M; Wyles D; Natha M; Zhu Y; Yang J; Kreter B; Brainard DM; Yun C; Carr V; Dore GJ, 2016, 'SOFOSBUVIR/LEDIPASVIR WITH AND WITHOUT RIBAVIRIN IN PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION RECEIVING OPIOID SUBSTITUTION THERAPY: PHASE 3 ION TRAILS', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 35, pp. 40 - 41

Alavi M; Janjua N; Yu A; Grebely J; Aspinall E; Innes H; Valerio H; Hayes P; Krajden M; Amin J; Law M; George J; Goldberg D; Hutchinson S; Dore G, 2016, 'DOES ALCOHOL DEPENDENCY EXPLAIN DIFFERENCES IN RATES OF DECOMPENSATED CIRRHOSIS AMONG PEOPLE WITH A HEPATITIS C NOTIFICATION? AN INTERNATIONAL COMPARISON', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, SPAIN, Barcelona, Vol. 64, pp. S462 - S463, presented at EASL International Liver Congress, SPAIN, Barcelona, 13 April 2016 - 17 April 2016, http://dx.doi.org/10.1016/S0168-8278(16)00776-5

Martinello M; Petoumenos K; Grebely J; Gane E; Hellard M; Shaw D; Sasdeusz J; Applegate T; Lamoury F; Yeung B; Maire L; Dore G; Matthews G, 2016, 'INCIDENCE OF HCV REINFECTION AMONG TREATED INDIVIDUALS WITH RECENTLY ACQUIRED INFECTION', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, SPAIN, Barcelona, Vol. 64, pp. S620 - S621, presented at EASL International Liver Congress, SPAIN, Barcelona, 13 April 2016 - 17 April 2016, http://dx.doi.org/10.1016/S0168-8278(16)01152-1

Grebely J; Marshall AD; Krahe M; Erratt A; Telenta J; Treloar C; Jones SC; Adey S; Bath N; How-Chow D; Byrne J; Harvey P; Dunlop AJ; Applegate TL; Lamoury F; Mowat Y; Jauncey M; Read P; Gilliver R; Smith J; Collie T; Dore GJ, 2016, 'A LIVER HEALTH PROMOTION INTERVENTION INTEGRATING NON-INVASIVE LIVER DISEASE SCREENING IN DRUG AND ALCOHOL SETTINGS: THE LIVERLIFE STUDY', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 35, pp. 40 - 40

Alavi M; Grebely J; Micallef M; Dunlop A; Balcomb A; Day C; Treloar C; Bath N; Haber P; Dore G, 2015, 'P0883 : Treatment for hepatitis C virus infection among people who inject drugs in the opioid substitution setting: The ethos study', in Journal of Hepatology, Elsevier, AUSTRIA, Vienna, Vol. 62, pp. s673, presented at 50th International Liver Congress of the European-Association-for-the-Study-of-the-Liver, AUSTRIA, Vienna, 22 April 2015 - 26 April 2015, http://dx.doi.org/10.1016/s0168-8278(15)31085-0

Reports

Wilkinson A; Griffin S; Hellard M; Stoové M; Dore G; Grebely J; Pedrana A; Doyle J; Thompson A; Hajarizadeh B; Aitken C; Broady T; Combo T, 2023, Australia’s progress towards hepatitis C elimination: Annual Report 2023, http://dx.doi.org/10.26190/4d4f-5n41

Shahbazi J; Farrell M; Byrne J; Ali R; Puszka B; Lim XQ; Cook J; Weiss R; Rodgers C; Dunlop A; Lintzeris N; Nielsen S; Grebely J; Zahra E; Degenhardt L; Byrne M, 2023, Considerations for delivering extended-release buprenorphine for opioid dependence in Australia: Preliminary lessons from the Community Long-Acting Buprenorphine (CoLAB) trial, NATIONAL DRUG AND ALCOHOL RESEARCH CENTRE, UNIVERSITY OF NEW SOUTH WALES, SYDNEY, 2020, RANDWICK, 355, http://dx.doi.org/10.26190/zemp-dx93

Wilkinson A; Hayes M; Hellard M; Stoové M; Dore G; Grebely J; Pedrana A; Doyle J; Thompson A; Hajarizadeh B; Alavi M; Aitken C; Broady T; Combo T, 2022, Australia's progress towards hepatitis C elimination: annual report 2022, http://dx.doi.org/10.26190/ge22-aq55

Brothers T; Degenhardt L, 2022, Time periods of altered risk for severe injection drug use-associated skin and soft-tissue infections: protocol for a self-controlled case series in New South Wales, Australia, 2001-2018, UCL Press, http://dx.doi.org/10.14324/000.rp.10157481, http://dx.doi.org/10.14324/000.rp.10157481

Bajis S; Dore G; Alavi M; McGregor S; Kwon A; Monaghan R; Iversen J; Martinello M; Buckland G; Guy R; Kaldor J; Grebely J, 2021, Progress towards hepatitis C elimination among Aboriginal and Torres Strait Islander people in Australia: monitoring and evaluation report, The Kirby Institute, UNSW Sydney, Sydney, Australia, https://kirby.unsw.edu.au/report/progress-towards-hepatitis-c-elimination-among-aboriginal-and-torres-strait-islander-people

Wilkinson A; Hellard M; Pedrana A; Alavi M; Stoove M; Doyle J; Aitken C; Dore G; Thompson A; Broady T; Grebely J; Hajarizadeh B, 2020, Australia’s progress towards hepatitis C elimination: annual report 2020, Burnet Institute and Kirby Institute, http://dx.doi.org/10.26190/unsworks/28056, https://kirby.unsw.edu.au/report/australias-progress-towards-hepatitis-c-elimination-annual-report-2020

Gibbs D; Grebely J; Larney S; Butler K; Sutherland R; Starr M; Karlsson A; Uporova J; Degenhardt L; Farrell M; Peacock A, 2019, Self-report and serological HCV status amongst people who inject drugs in NSW and ACT, National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Drug Trends Bulletin August 2019, http://dx.doi.org/10.26190/5d788a487ac61, https://ndarc.med.unsw.edu.au/sites/default/files/ndarc/resources/4.%20DBS%20and%20HCV%20self%20report%20bulletin.pdf

Wilkinson A; Hellard M; Pedrana A; Alavi M; Stoove M; Doyle J; Aitken C; Dore G; Thompson A; Grebely J; Hajarizadeh B, 2019, Australia’s progress towards hepatitis C elimination: annual report 2019, Burnet Institute and Kirby Institute, http://dx.doi.org/10.26190/unsworks/28055, https://kirby.unsw.edu.au/report/australias-progress-towards-hepatitis-c-elimination-annual-report-2019

Kwon J; Gray R; Dore G; Grebely J; Guy R; Hajarizadeh B; Cunningham E, 2017, 2017 Estimates and Projections of the Hepatitis C Virus Epidemic in NSW: Summary Report, Sydney: Kirby Institute, UNSW Sydney

Theses / Dissertations

Valerio H, 2021, Elimination of hepatitis C virus among people who inject drugs in Australia

Bartlett SR, 2017, Molecular epidemiology of recently acquired hepatitis C virus infection in Australia

Preprints

Kwon J; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Power C; Estes C; Razavi H; Gray RT, Australia on Track to Achieve Who HCV Elimination Targets Following Rapid Initial DAA Treatment Uptake: A Modelling Study, http://dx.doi.org/10.2139/ssrn.3213670

Koopsen J; Matthews G; Rockstroh JK; Applegate TL; Bhagani SR; Grebely J; Rauch A; Sacks-Davis R; Ingiliz P; Boesecke C; Rebers S; Feld J; Bruneau J; Martinello M; Hellard ME; Dore GJ; Schinkel J; van der Valk M; Study Group REACT, Hepatitis C Virus Transmission Dynamics in a Global Cohort of Men Who Have Sex with Men with Recently Acquired Infection, http://dx.doi.org/10.2139/ssrn.4125248

Shih STF; Cheng Q; Carson J; Valerio H; Sheehan Y; Gray RT; Cunningham EB; Kwon J; Lloyd AR; Dore GJ; Wiseman V; Grebely J, Optimizing Point-of-Care Testing Strategies for Diagnosis and Treatment of Hepatitis C Virus Infection in Australia: A Model-Based Cost-Effectiveness Analysis, http://dx.doi.org/10.2139/ssrn.4267510

Shih STF; Cheng Q; Carson J; Valerio H; Sheehan Y; Gray RT; Cunningham EB; Kwon J; Lloyd AR; Dore GJ; Wiseman V; Grebely J, Optimizing Point-of-Care Testing Strategies for Diagnosis and Treatment of Hepatitis C Virus Infection in Australia: A Model-Based Cost-Effectiveness Analysis, http://dx.doi.org/10.2139/ssrn.4267527

Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; McManus H; Butler T; Cunningham EB; Vickerman P; Martin NK; McHutchison JG; Brainard DM; Treloar C; Chambers GM; Grant L; Mcgrath C; Lloyd AR; Dore GJ; Group S-CS, Reduced Hepatitis C Incidence Associated with Rapid Treatment Scale-Up in Australian Prisons: Treatment-as-Prevention in the SToP-C Study, http://dx.doi.org/10.2139/ssrn.3709824

Other

Dore GJ; Grebely J, 2017, Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030, Elsevier, http://dx.doi.org/10.1016/j.jhep.2017.03.035

Grebely J; Swan T; Hickman M; Bruneau J; Bruggmann P; Dalgard O; Litwin A; Backmund M; Dore GJ, 2017, Contradictory advice for people who inject drugs in the 2016 EASL Recommendations on Treatment of Hepatitis C, Elsevier, http://dx.doi.org/10.1016/j.jhep.2016.12.028

Back to profile page